We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Ionis Pharmaceuticals Inc | NASDAQ:IONS | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.69 | -1.72% | 39.47 | 39.29 | 40.06 | 40.18 | 39.31 | 40.16 | 1,300,598 | 21:27:36 |
From Nov 2023 to May 2024
By Ben Glickman
Ionis Pharmaceuticals and AstraZeneca's Wainua has been approved by the U.S. Food and Drug Administration for treating a symptom of a rare genetic disease.
The FDA approved Wainua, which has generic name eplontersen, for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.
Ionis said Wainua would be available in the U.S. in January. Regulatory reviews elsewhere in the world are currently underway.
The disease, also known as hAATR, can cause polyneuropathy, a form of nerve damage. The companies said Wainua is the only approved medicine for treating polyneuropathy from hATTR.
The approval was based on a 35-week interim analysis from a Phase 3 study.
Write to Ben Glickman at ben.glickman@wsj.com
(END) Dow Jones Newswires
December 21, 2023 19:23 ET (00:23 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year Ionis Pharmaceuticals Chart |
1 Month Ionis Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
